Mark L Metersky1, Radmila Choate2, Timothy R Aksamit3, Douglas Conrad4, Nicole C Lapinel5, Diego J Maselli6, Pamela J McShane7. 1. Division of Pulmonary, Critical Care and Sleep Medicine, University of Connecticut School of Medicine, USA. Electronic address: Metersky@uchc.edu. 2. University of Kentucky College of Public Health, USA. 3. Division of Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA. 4. Division of Pulmonary, Critical Care and Sleep Medicine University of California San Diego, CA, USA. 5. Section of Pulmonary/Critical Care & Allergy/Immunology, Louisiana State University Health Sciences Center, LA,, USA. 6. Division of Pulmonary Diseases & Critical Care, UT Health San Antonio, TX, USA. 7. Division of Pulmonary and Critical Care, University of Texas Health Science Center at Tyler, TX, USA.
Abstract
INTRODUCTION: Little information is available about Stenotrophomonas maltophilia in patients with bronchiectasis. We analyzed data from the US Bronchiectasis and NTM Research Registry to determine its prevalence and association with patient characteristics and severity of disease. METHODS: Baseline and follow-up data were entered into a central web-based database. Patients were grouped into four cohorts based on their baseline cultures: 1) S. maltophilia, no Pseudomonas aeruginsosa, 2) P. aeruginosa, no S. maltophilia, 3) No pathogens, 4) Pathogens other than P. aeruginosa and S. maltophilia. The association between S. maltophilia, demographic characteristics, pulmonary function, exacerbations and hospitalizations was assessed at baseline and one year follow-up. RESULTS: Among 2659 patients, 134 (5.0%) had grown S. maltophilia at baseline. The prior exacerbation rate at baseline was similar in patients with S. maltophilia and P. aeruginosa, but significantly higher than the other two groups. Hospitalizations were more frequent in patients with S. maltophilia or P. aeruginosa. Pre-bronchodilator FEV1 among S. maltophilia patients was between that of Pseudomonas patients and patients without either organism, but was not significantly different from any of the other groups. For all risk-adjusted one-year outcomes, patients with S. maltophilia had a non-significant trend towards worse outcomes compared to patients without P. aeruginosa, but were more similar to patients with P aeruginosa. DISCUSSION: Bronchiectasis patients with S. maltophilia may have worse outcomes than patients without this organism or without P. aeruginosa; further study is needed to determine if the non-significant trends we note are clinically significant.
INTRODUCTION: Little information is available about Stenotrophomonas maltophilia in patients with bronchiectasis. We analyzed data from the US Bronchiectasis and NTM Research Registry to determine its prevalence and association with patient characteristics and severity of disease. METHODS: Baseline and follow-up data were entered into a central web-based database. Patients were grouped into four cohorts based on their baseline cultures: 1) S. maltophilia, no Pseudomonas aeruginsosa, 2) P. aeruginosa, no S. maltophilia, 3) No pathogens, 4) Pathogens other than P. aeruginosa and S. maltophilia. The association between S. maltophilia, demographic characteristics, pulmonary function, exacerbations and hospitalizations was assessed at baseline and one year follow-up. RESULTS: Among 2659 patients, 134 (5.0%) had grown S. maltophilia at baseline. The prior exacerbation rate at baseline was similar in patients with S. maltophilia and P. aeruginosa, but significantly higher than the other two groups. Hospitalizations were more frequent in patients with S. maltophilia or P. aeruginosa. Pre-bronchodilator FEV1 among S. maltophilia patients was between that of Pseudomonas patients and patients without either organism, but was not significantly different from any of the other groups. For all risk-adjusted one-year outcomes, patients with S. maltophilia had a non-significant trend towards worse outcomes compared to patients without P. aeruginosa, but were more similar to patients with P aeruginosa. DISCUSSION: Bronchiectasis patients with S. maltophilia may have worse outcomes than patients without this organism or without P. aeruginosa; further study is needed to determine if the non-significant trends we note are clinically significant.
Authors: Jeffrey Fong Ting Chau; Mianne Lee; Martin Man Chun Chui; Mullin Ho Chung Yu; Jasmine Lee Fong Fung; Christopher Chun Yu Mak; Christy Shuk-Kuen Chau; Ka Ka Siu; Jacqueline Hung; Kit San Yeung; Anna Ka Yee Kwong; Christopher O'Callaghan; Yu Lung Lau; Chun-Wai Davy Lee; Brian Hon-Yin Chung; So-Lun Lee Journal: Front Genet Date: 2022-08-08 Impact factor: 4.772